{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:07:06Z","timestamp":1775556426387,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Capital Science and Technology Leading Talent Training Project","award":["Z191100006119017"],"award-info":[{"award-number":["Z191100006119017"]}]},{"name":"Beijing Hospitals Authority Ascent Plan","award":["DFL20190803"],"award-info":[{"award-number":["DFL20190803"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00280-023-04536-5","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T12:02:42Z","timestamp":1683806562000},"page":"523-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0116-4387","authenticated-orcid":false,"given":"Chaoying","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"issue":"3","key":"4536_CR1","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/cas.13947","volume":"110","author":"L Wang","year":"2019","unstructured":"Wang L, Yang C, Xie C et al (2019) Pharmacologic characterization of fuzuloparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci 110(3):1064\u20131075. https:\/\/doi.org\/10.1111\/cas.13947","journal-title":"Cancer Sci"},{"key":"4536_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","volume":"24","author":"J Morales","year":"2014","unstructured":"Morales J, Li L, Fattah FJ et al (2014) Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 24:15\u201328","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"4536_CR3","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1038\/s41467-018-05031-9","volume":"9","author":"J Michelena","year":"2018","unstructured":"Michelena J, Lezaja A, Teloni F et al (2018) Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. Nat Commun 9:2678","journal-title":"Nat Commun"},{"issue":"10","key":"4536_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A (2021) Fuzuloparib: first approval. Drugs 81(10):1221\u20131226. https:\/\/doi.org\/10.1007\/s40265-021-01541-x","journal-title":"Drugs"},{"issue":"3","key":"4536_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00432-019-03097-6","volume":"146","author":"J Luo","year":"2020","unstructured":"Luo J, Dai X, Hu H et al (2020) Fuzuloparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1\/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. J Cancer Res Clin Oncol 146(3):721\u2013737. https:\/\/doi.org\/10.1007\/s00432-019-03097-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"4536_CR6","doi-asserted-by":"publisher","first-page":"819714","DOI":"10.3389\/fonc.2022.819714","volume":"12","author":"X Li","year":"2022","unstructured":"Li X, Yuan X, Wang Z et al (2022) Chidamide reverses fluzoparib resistance in triple-negative breast cancer cells. Front Oncol 12:819714. https:\/\/doi.org\/10.3389\/fonc.2022.819714","journal-title":"Front Oncol"},{"key":"4536_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01511","author":"N Li","year":"2022","unstructured":"Li N, Zhang Y, Wang J et al (2022) Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.21.01511","journal-title":"J Clin Oncol"},{"key":"4536_CR8","doi-asserted-by":"publisher","first-page":"11833","DOI":"10.2147\/CMAR.S265327","volume":"12","author":"L Zhu","year":"2020","unstructured":"Zhu L, Zhu C, Wang X et al (2020) The combination of icotinib hydrochloride and fluzoparib enhances the radiosensitivity of biliary tract cancer cells. Cancer Manag Res 12:11833\u201311844. https:\/\/doi.org\/10.2147\/CMAR.S265327","journal-title":"Cancer Manag Res"},{"issue":"3","key":"4536_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.21147\/j.issn.1000-9604.2020.03.08","volume":"32","author":"H Li","year":"2020","unstructured":"Li H, Liu R, Shao B et al (2020) Phase I dose-escalation and expansion study of PARP inhibitor, fuzuloparib (SHR3162), in patients with advanced solid tumors. Chin J Cancer Res 32(3):370\u2013382. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2020.03.08","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"4536_CR10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/bcp.15035","volume":"88","author":"X Jiang","year":"2022","unstructured":"Jiang X, Tao Y, Liu Y et al (2022) A randomized, open-label, two-period crossover bridging study on fuzuloparib capsules of different specifications in healthy Chinese volunteers. Br J Clin Pharmacol 88(3):1087\u20131093. https:\/\/doi.org\/10.1111\/bcp.15035","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4536_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/17425255.2021.1881480","volume":"17","author":"M Wu","year":"2021","unstructured":"Wu M, Li X, Sun J et al (2021) A phase I study of fuzuloparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers. Expert Opin Drug Metab Toxicol 17(4):503\u2013508. https:\/\/doi.org\/10.1080\/17425255.2021.1881480","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4536_CR12","unstructured":"Center for drug evaluation. National Medical Product Administration. Fuzuloparib capsule label. https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=441ef8f40d36fd8333bf5b07bf857683. Accessed 19 Jun 2022"},{"key":"4536_CR13","unstructured":"U.S. Food and Drug Administration. Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical Implications, Guidance for Industry. 2017. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-study-design-data-analysis-and-clinical-implications-guidance. Accessed 19 Jun 2022"},{"key":"4536_CR14","unstructured":"Center for drug evaluation. National Medical product Administration. Drug interaction research technical guideline (to try out). https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=e0293bfd34a7c44a93382776199101bb. Accessed 19 Jun 2022"},{"issue":"7","key":"4536_CR15","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1111\/bcp.15256","volume":"88","author":"Y Bian","year":"2022","unstructured":"Bian Y, Meng J, Ma S et al (2022) Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers. Br J Clin Pharmacol 88(7):3307\u20133320. https:\/\/doi.org\/10.1111\/bcp.15256","journal-title":"Br J Clin Pharmacol"},{"key":"4536_CR16","unstructured":"Declaration of Helsinki. World Medical Association Declaration of Hensinki, adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and last amended by the 64th General Assembly, Fortaleza, Brazil, October 2013. Available from: http:\/\/www.health.uct.ac.za\/sites\/default\/files\/image_tool\/images\/116\/Helsinki%202013.pdf. Accessed 19 Jun 2022"},{"key":"4536_CR17","unstructured":"International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. Guideline for good clinical principles. Available from: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R2__Step_4_2016_1109.pdf. Accessed 19 Jun 2022"},{"issue":"1","key":"4536_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00280-021-04376-1","volume":"89","author":"X Chen","year":"2022","unstructured":"Chen X, Yang F, Zhao J et al (2022) Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers. Cancer Chemother Pharmacol 89(1):141\u2013148. https:\/\/doi.org\/10.1007\/s00280-021-04376-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4536_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jcph.562","volume":"56","author":"L Liu","year":"2016","unstructured":"Liu L, Bello A, Dresser MJ et al (2016) Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. J Clin Pharmacol 56(2):143\u2013151. https:\/\/doi.org\/10.1002\/jcph.562","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"4536_CR20","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cpt.1943","volume":"108","author":"MR Durk","year":"2020","unstructured":"Durk MR, Jones NS, Liu J et al (2020) Understanding the effect of hydroxypropyl-\u03b2-cyclodextrin on fenebrutinib absorption in an itraconazole-fenebrutinib drug-drug interaction study. Clin Pharmacol Ther 108(6):1224\u20131232. https:\/\/doi.org\/10.1002\/cpt.1943","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4536_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1124\/jpet.121.000620","volume":"378","author":"RS Sane","year":"2021","unstructured":"Sane RS, Cheung KWK, Cho E et al (2021) Evaluation of ipatasertib interactions with itraconazole and coproporphyrin i and iii in a single drug interaction study in healthy subjects. J Pharmacol Exp Ther 378(2):87\u201395. https:\/\/doi.org\/10.1124\/jpet.121.000620","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4536_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jcph.1016","volume":"58","author":"X Liu","year":"2018","unstructured":"Liu X, Zhang Y, Chen Q et al (2018) Pharmacokinetic drug interactions of apatinib with rifampin and itraconazole. J Clin Pharmacol 58(3):347\u2013356. https:\/\/doi.org\/10.1002\/jcph.1016","journal-title":"J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04536-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T16:04:28Z","timestamp":1684339468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04536-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["4536"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04536-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"5 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author reports no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol, protocol amendments, and all applicable documents (including informed consent form) were reviewed and approved by the Ethics Committee of Xuanwu Hospital Capital Medical University (2019 No.018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients prior to screening.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}